Read the latest insights on emerging CAR T therapies. This personalized treatment has shown promising results in certain types of cancers by harnessing the power of the immune system to fight disease.
Scientists believe prostaglandin F2 receptor negative regulator (PTGFRN) is a possible target for chimeric antigen receptor (CAR) T-cell therapy in patients with glioblastoma (GBM).
Researchers report the safety of a novel approach to insulate edited cells from chimeric antigen receptor (CAR) selection and attack.